核苷和核苷酸类药物抗HBV治疗过程中发生肝细胞癌的临床特征

张英; 刘明; 彭晓华; 孙琳琳; 王耀辉; 谢仕斌

doi:10.3969/j.issn.1001-5256.2017.04.016

核苷和核苷酸类药物抗HBV治疗过程中发生肝细胞癌的临床特征

DOI: 10.3969/j.issn.1001-5256.2017.04.016

中山大学肝脏病医院，中山大学附属第三医院感染科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2440
- HTML全文浏览量: 8
- PDF下载量: 497
- 被引次数: 0
出版历程
- 出版日期: 2017-04-20

Clinical features of patients developing primary hepatocellular carcinoma during anti-HBV therapy with nucleos (t) ide analogues

Liver Hospital of Sun Yat-sen University, Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University

摘要

摘要: 目的总结核苷和核苷酸类药物（NAs）抗HBV治疗过程中发生肝细胞癌的临床特征。方法收集2008年1月-2014年9月在中山大学附属第三医院初次诊断为肝细胞癌的患者542例,均为慢性HBV感染者,按是否规范使用NAs治疗分为抗病毒组（130例）及未抗病毒组（412例）,回顾性分析比较2组患者的临床资料,包括年龄、性别、肿瘤家族史、HBV感染时间、确诊肝硬化时间、饮酒史、糖尿病史、用药史及实验室检查指标、肝组织病理和影像学检查结果等。符合正态分布的计量资料2组间比较采用t检验,符合偏态分布的计量资料2组间比较采用Mann-Whitney U检验,计数资料2组间比较采用χ2检验。结果与未抗病毒组比较,抗病毒组肝硬化患者的比例显著升高（90.0%vs 78.4%,χ2=8.528,P=0.003）;HBe Ag阳性率明显升高（29.4%vs18.5%,χ2=6.794,P=0.009）。抗病毒组HBV DNA构成与未抗病毒组比较,差异有统计学意义（χ2=173.142,P<0.001）。抗病毒组ALT...
- 肝炎病毒,乙型 /
- 癌,肝细胞 /
- 核苷类 /
- 核苷酸类
Abstract: Objective To investigate the clinical features of patients developing hepatocellular carcinoma ( HCC) during anti-hepatitis B virus ( HBV) therapy with nucleos ( t) ide analogues ( NAs) . Methods A total of 542 patients who were diagnosed with HCC for the first time in The Third Affiliated Hospital of Sun Yat-Sen University from January 2008 to September 2014 were enrolled, and they all had chronic HBV infection. According to the presence or absence of standard therapy with NAs, they were divided into antiviral group ( 130 patients) and non-antiviral group ( 412 patients) . A retrospective analysis was performed for their clinical data, including age, sex, family history of tumor, duration of HBV infection, the time when a confirmed diagnosis of liver cirrhosis was made, history of drinking, history of diabetes, history of medication, laboratory parameters, liver pathology, and imaging findings, and these data were compared between the two groups.The t-test was used for comparison of normally distributed continuous data between groups, the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the non-antiviral group, the antiviral group had significant increases in the proportion of patients with liver cirrhosis ( 90. 0% vs 78. 4%, χ2= 8. 528, P = 0. 003) and HBe Ag-positive rate ( 29. 4% vs 18. 5%, χ2= 6. 794, P = 0. 009) .There was a significant difference in the constitution of HBV DNA between the two groups ( χ2= 173. 142, P < 0. 001) , as well as significant differences in alanine aminotransferase, gamma-glutamyl transpeptidase, and alpha-fetoprotein ( all P < 0. 001) . Compared with the non-antiviral group, the antiviral group had a higher proportion of patients with early-or intermediate-stage liver cancer, smaller and fewer cancer lesions, and a lower proportion of patients with vascular invasion or distant metastasis ( all P < 0. 001) . Among the patients in the antiviral group, 80% ( 104/130) developed HCC within 5 years of anti-HBV therapy. Conclusion Some patients with chronic HBV infection who receive long-term NAs as the anti-HBV therapy still develop HCC, especially those with liver cirrhosis, and most of these cases occur within 5 years of anti-HBV therapy. Most patients treated with NAs are diagnosed at the early stage of HCC, suggesting that standard follow-up is of vital importance.
- hepatitis B virus /
- carcinoma, hepatocellular /
- nucleosides /
- nucleotides

HTML全文

参考文献(17)

[1]HALEGOUA-DE MARZIO D, HANN HW.Then and now:the progress in hepatitis B treatment over the past 20 years[J].World J Gastroenterol, 2014, 20 (2) :401-413.

[2]YE XQ, GAO FY, SUN L, et al.Improvement of improve the two years survival rate of patients with hepatitis B virus-related primary liver cancer after antiviral treatment[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (3) :304-310. (in Chinese) 叶协琼, 高方媛, 孙乐, 等.抗病毒治疗提高乙型肝炎病毒相关原发性肝癌患者两年生存率[J/CD].中华实验和临床感染病杂志电子版, 2016, 10 (3) :304-310.

[3]LIN CL, KAO JH.Risk stratification for hepatitis B virus related hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2013, 28 (1) :10-17.

[4] BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[5]YANG HI, YUEN MF, CHAN HL, et al.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) :development and validation of a predictive score[J].Lancet Oncol, 2011, 12 (6) :568-574.

[6]European Association ror the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[7]WONG GL, WONG VW, CHAN HL.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B[J].J Viral Hepat, 2014, 21 (12) :825-834.

[8] WATANABE T, TOKUMOTO Y, JOKO K, et al.Effects of longterm entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients[J].Hepatol Int, 2016, 10 (2) :320-327.

[9]SINGAL AK, SALAMEH H, KUO YF, et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Aliment Pharmacol Ther, 2013, 38 (2) :98-106.

[10]HOSAKA T, SUZUKI F, KOBAYASHI M, et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology, 2012, 58 (1) :98-107.

[11]LIAW YF, SHEEN IS, LEE CM, et al.Tenofovir disoproxil fumarate (TDF) , emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease[J].Hepatology, 2011, 53 (1) :62-72.

[12] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al.Virological suppression does not prevent the development of hepatocellular carcinoma in HBe Ag-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral (s) starting with lamivudine monotherapy:results of the nationwide HEPNET.Greece cohort study[J].Gut, 2011, 60 (8) :1109-1116.

[13] SINGAL AK, SALAMEH H, KUO YF, et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Aliment Pharmacol Ther, 2013, 38 (2) :98-106.

[14]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[15]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatmen of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[16]Biliary Tract Group, Chinese Society of Surgery, Chinese Medical Association Guidelines for the diagnosis and treatment of hepatolithiasis[J].Chin J Intect Dis, 2001, 40 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会, 肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 40 (1) :56-62.

[17] SHEN YC, HSU C, CHENG CC, et al.A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B:a novel approach by using meta-regression[J].Oncology, 2012, 82 (5) :275-289.

施引文献

资源附件(0)

访问统计